Sabcomeline
Sabcomeline
Sabcomeline (pronounced: sab-co-me-line) is a pharmacological agent that was developed for the treatment of Alzheimer's disease and schizophrenia. It is a muscarinic M1 and M4 receptor agonist.
Etymology
The term "Sabcomeline" is derived from the chemical name of the drug, which is "Sabcomeline hydrochloride". The prefix "Sab" is an abbreviation of the company that first developed the drug, Sandoz (now Novartis), and "comeline" is derived from the chemical structure of the drug, which is a comenic acid derivative.
Pharmacology
Sabcomeline is a selective M1 and M4 muscarinic receptor agonist. It was developed to enhance cholinergic neurotransmission in the brain, which is impaired in conditions such as Alzheimer's disease and schizophrenia. The M1 and M4 receptors are the most abundant muscarinic receptors in the brain and are involved in a variety of cognitive functions, including memory and attention.
Clinical Trials
Sabcomeline has been tested in several clinical trials for its potential use in the treatment of Alzheimer's disease and schizophrenia. However, the results have been mixed and the drug has not been approved for use in these conditions.
Related Terms
- Agonist
- Alzheimer's disease
- Cholinergic
- Clinical trials
- Muscarinic
- Novartis
- Pharmacological
- Schizophrenia
External links
- Medical encyclopedia article on Sabcomeline
- Wikipedia's article - Sabcomeline
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski